Over the past two months, Univalor has granted two new licences for the commercialization of antibodies to EMD Millipore, an international company of Merck KgaA Group providing services and products in the fields of "Biosciences, laboratory products and Process Solutions ". These antibodies are useful research tools, especially to study the involvement of a protein in a particular disease and in order to develop new efficient treatments.


Montreal May 20, 2015 - The results of a study conducted by Dr. Alexandre Prat and researchers from the Research Centre of the CHUM (CRCHUM), reported in an article published today in Annals of Neurology, demonstrates the beneficial potential of a molecule called MCAM which, if blocked, can delay the onset of multiple sclerosis and significantly slow down its progression.


Montreal, April 16, 2015 – NEOMED announced today a new collaboration with Univalor, the Centre de recherche du centre hospitalier de l'Université de Montréal (CRCHUM), and Dr. Nicolas Noiseux for the development of an innovative therapy for the treatment of ischemic heart injury. Dr. Nicolas Noiseux and colleague Dr. Shant Der Sarkissian have identified a lead molecule and target stimulating powerful endogenous protective mechanisms that increase cell and tissue viability to hypoxic stress, reducing the impact of a heart attack.



Montreal,  April  7th  2015  - AmorChem  is  very  proud  to  announce  that  it  has  entered  into  an  agreement with Hôpital Maisonneuve-­‐Rosemont (HMR) and Univalor to participate in the financing of R&D  activities  at  the  Personalized  Cancer  ImmunoTherapy  Program  (PCITP).  This  is  the  second  AmorChem financing for the PCITP, the first being the product of an existing agreement with HMR, the Université of Montréal (UdeM), Institute for Research in Immunology and Cancer and its Institute for Research in Immunology and Cancer —

Univalor is pleased to highlight the announcement of the CHU Sainte-Justine about the creation of a Center for Rare Genetic Disorders with support from Rio Tinto Alcan. Made possible by a donation of $3 million dollars from Rio Tinto Alcan, the Center for Rare Genetic Disorders, the only facility of its kind in Quebec , will allow 50,000 children and their families to receive better care for their condition.